Cell capable of expressing exogenous GITR ligand
Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.
1. A pharmaceutical composition comprising an excipient and an immune cell capable of expressing an exogenous Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand (GITRL) derivative, wherein said GITRL derivative is a fusion protein consisting of amino acids 50-177 of SEQ ID NO: 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×10 3 to 1×10 11 cells/mL of said immune cell.
2. The pharmaceutical composition of claim 1 wherein said immunoglobulin is IgG2.
3. The pharmaceutical composition of claim 1 wherein said composition comprises 1×10 4 to 1×10 10 cells/mL of said immune cell.
4. The pharmaceutical composition of claim 1 wherein said composition comprises 1×10 5 to 1×10 9 cells/mL of said immune cell.
5. A pharmaceutical composition comprising an excipient and an inactivated tumor cell capable of expressing an exogenous Glucocorticoid-Induced Tumor necrosis factor Receptor Ligand (GITRL) derivative, wherein said GITRL derivative is a fusion protein consisting of amino acids 50-177 of SEQ ID NO: 6 fused to an Fc fragment of an immunoglobulin, wherein the composition comprises 1×10 3 to 1×10 11 cells/mL of said inactivated tumor cell.
6. The pharmaceutical composition of claim 5 wherein said immunoglobulin is IgG2.
7. The pharmaceutical composition of claim 5 wherein said composition comprises 1×10 4 to 1×10 10 cells/mL of said inactivated tumor cell.
8. The pharmaceutical composition of claim 5 wherein said composition comprises 1×10 5 to 1×10 9 cells/mL of said inactivated tumor cell.